

# Aegon Maraton Active Mixed Investment Fund CZK series

## GENERAL INFORMATION

Fund Manager:	AEGON Hungary Fund Manager Ltd.
Custodian:	Raiffeisen Bank Zrt.
Main distributor:	AEGON Hungary Fund Manager Ltd.
Benchmark composition:	100% RMAX Index
ISIN code:	HU0000716055
Start:	03/17/2016
Currency:	CZK
Total Net Asset Value of the whole Fund:	22,540,089,484 HUF
Net Asset Value of CZK series:	CZK
Net Asset Value per unit:	1.070491 CZK

## INVESTMENT POLICY OF THE FUND:

The objective of the Fund is to provide capital return for the investors within the appropriate risk limits. The aim of the Fund is to achieve the highest possible return for a given risk level by buying undervalued stocks and fixed income assets and selling overvalued instruments. The Fund is allowed to buy shares, bonds and other instruments, to open short positions on the spot market, to take long and short forward and future positions. Moreover, the Fund can trade on the option market. The portfolio of the Fund is separated into three classes according to their investment objective: Instruments of the first class consist of long positions of long term, fundamentally undervalued, and short positions of overvalued equities. The method of stock picking is identical with the applied methods of Aegon equity related funds and mainly concentrate to the CEE regional markets, although the Fund is allowed to invest in other emerging and developed market instruments. The second class of the Fund's instruments implement the top-down equity strategy of Aegon Asset Management Co., mainly with long and short positions on the futures markets. These positions are based on the scores of the so-called "quadrant model", which is the internal asset allocation model of the Asset Management Company. Instruments of the third class involve the fixed income part of the Fund. The aim of the third class is to reach or exceed the performance of the RMAX Index. The target weight of the first and second classes altogether is 45%.

## DISTRIBUTORS

Raiffeisen Bank Zrt.

## NET YIELD PERFORMANCE OF THE SERIES:

Interval	Yield of note	Benchmark yield
From start	1.53 %	0.48 %
2019	0.00 %	0.23 %
2018	1.74 %	0.31 %
2017	2.26 %	0.20 %

## RISK INDICATORS FOR THE LAST 12 MONTHS:

Annualized standard deviation of the fund's weekly yields:	no data
Annualized standard deviation of the benchmark's weekly yields:	no data
WAM (Weighted Average Maturity):	2.52 years
WAL (Weighted Average Life):	3.26 years

## INVESTMENT HORIZON:

Suggested minimum investment period:



Risk and Reward Profile:



## TOP 5 POSITIONS

Asset	Type	Counterparty / issuer	Maturity
ISHARES DJ EuroBANKS ETF	investment note	ISHARES DJ EuroBANKS ETF (DE)	
Adventum TRIUM Zártörű Ingatlan Befektetési Alap új	investment note	Adventum TRIUM Zártörű Ingatlan Befektetési Alap (HU)	
Adventum MAGIS Zártörű Alapok Alapja	investment note	Adventum MAGIS Zártörű Alapok (HU)	
KAZAKS 2.375 11/09/28	interest-bearing	Kazakh állam (KZ)	2028. 11. 09.
ERSTBK PERP 2021/10/15 8,875% EUR	interest-bearing	ERSTE BANK AG (AT)	2021. 10. 15.

## MARKET SUMMARY:

In November, we got the answers to two questions that preoccupied investors throughout the year. First, we have finally found out who will be president of the United States in the next four years, and the other, perhaps more importantly, in the current circumstances, is when we can expect to be vaccinated against the corona virus. The U.S. presidential election was won by former President Barack Obama's Vice President Joe Biden. More importantly, in the case of the corona virus, we can finally see the light at the end of the tunnel. In November, three drug companies announced that the Phase 3 trials were extremely successful, and mass vaccinations could begin as early as the first half of December. U.S. stock market indices rose significantly in November on news that the vaccine is about to be distributed in the near future. The Russel 2000 index was able to break through the 2018 level and hit a new all-time high, and the Dow Jones index broke the psychologically important 30,000 mark for the first time in its history. Stock markets are extremely optimistic about the future and seem to price in the best case scenario. It is true that starting to vaccinate the population next spring will be of great help to the economy, but stock markets are currently pricing that by next summer, everything will be back to pre-Covid-19. At least that what share prices and market expectations reflect. The European economy is mixed. Although the German consumer sentiment index fell from the previous -3.1 to -6.7 in November, below the expected 51.5 in November. The corona virus continues to spread uncontrollably in Hungary. Nothing has been implemented from the previously announced economic stimulus package, and the Hungarian forint shows the vulnerability of the economy as well. Although the domestic currency has not weakened against regional currencies, it cannot gain significant ground against the euro. The fund achieved a positive return in November. We increased the equity weighting to 45% at the beginning of November, which we further increased to 50% during the month. Most of the fund's performance in November was produced by the banking sector, and within that, Greek banks contributed the most. In addition, the solar and fintech sectors performed well too. What reduced the fund's performance last month was the gold exposure. In November, we further increased our emerging market weight after believing that emerging markets are in a more stable position both economically and in the fight against the virus. We further increased value-based investments during the month, reducing the growth sector proportionately. The weakening of the US dollar will also greatly help these economies.

## ASSET ALLOCATION OF THE FUND ON 11/30/2020

Asset type	Weight
Collective securities	31.84 %
Corporate bonds	22.54 %
International equities	14.96 %
Government bonds	12.97 %
Hungarian equities	9.70 %
Current account	8.58 %
Liabilities	-1.71 %
Receivables	1.03 %
Market value of open derivative positions	0.09 %
total	100.00 %
Derivative products	61.13 %
Net corrected leverage	100.86 %

## Assets with over 10% weight

There is no such instrument in the portfolio